Acute Lymphoblastic Leukemia: What to Do When Induction Chemotherapy Did Not Achieve Complete Remission
Patients with acute lymphoblastic leukemia (ALL) who do not reach the defined complete remission criteria at the end of induction require a structured next step. This protocol addresses that situation — consolidation following incomplete induction response.
Previous Treatment & the Goals It Did Not Achieve
The prior line was induction chemotherapy, typically combining:
vincristine
daunorubicin or doxorubicin
prednisone or dexamethasone
cyclophosphamide (select patients)
pegaspargase (select patients)
inotuzumab ozogamicin, ofatumumab, or rituximab (select patients)
intrathecal methotrexate + cytarabine + corticosteroids (CNS-directed)
Remission goals not fully met (approximately 4 weeks after start):
- No more than 5% blast cells in the bone marrow
- No blasts detected in the blood
- Blood cell counts returned to normal or near-normal
- All signs and symptoms of ALL resolved
Next Step: Consolidation (Partial Overview)
Consolidation — the phase that follows induction — continues CNS-directed treatment; the full protocol specifies how the approach is determined and which patients may be considered for additional interventions based on their individual profile.
References
- For patients who are MRD-positive, blinatumomab (Blincyto®) is often the recommended treatment.
- Blinatumomab is a liquid administered slowly into a vein by IV as a continuous infusion over a period of 28 days for each cycle.
- For most patients who are MRD-negative, consolidation consists of multiagent chemotherapy.
- Consolidation is usually given in cycles over 4 to 6 months.
- As part of consolidation, some patients in remission may receive a stem cell transplant.
- Doctors usually recommend stem cell transplantation for patients who are likely to relapse due to high-risk genetic features, or for patients who have high rates of MRD after induction.
View source ↗